These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 16509865

  • 1. Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
    Lin ZY, Chuang WL, Chuang YH, Yu ML, Hsieh MY, Wang LY, Tsai JF.
    J Gastroenterol Hepatol; 2006 Feb; 21(2):398-405. PubMed ID: 16509865
    [Abstract] [Full Text] [Related]

  • 2. Amphotericin B up-regulates angiogenic genes in hepatocellular carcinoma cell lines.
    Lin ZY, Chuang WL, Chuang YH.
    Eur J Clin Invest; 2009 Mar; 39(3):239-45. PubMed ID: 19260954
    [Abstract] [Full Text] [Related]

  • 3. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, Zhou LX.
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [Abstract] [Full Text] [Related]

  • 4. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [Abstract] [Full Text] [Related]

  • 5. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC).
    Kohno H, Nagasue N, Hayashi T, Yamanoi A, Uchida M, Ono T, Yukaya H, Kimura N, Nakamura T.
    Hepatogastroenterology; 1996 Apr; 43(12):1405-9. PubMed ID: 8975939
    [Abstract] [Full Text] [Related]

  • 6. Phenotypic diversity of intrahepatic and extrahepatic cholangiocarcinoma on aspiration cytology and core needle biopsy: case series and review of the literature.
    Chaudhary HB, Bhanot P, Logroño R.
    Cancer; 2005 Aug 25; 105(4):220-8. PubMed ID: 15952192
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H, Shiratori K, Yamamoto M, Takasaki K, Nakano M.
    J Gastroenterol Hepatol; 2006 May 25; 21(5):869-73. PubMed ID: 16704538
    [Abstract] [Full Text] [Related]

  • 8. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD.
    Cancer; 2004 Aug 01; 101(3):578-86. PubMed ID: 15274071
    [Abstract] [Full Text] [Related]

  • 9. Primary liver cancers with nonalcoholic steatohepatitis.
    Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohwada S, Mori M.
    Eur J Gastroenterol Hepatol; 2007 Oct 01; 19(10):827-34. PubMed ID: 17873605
    [Abstract] [Full Text] [Related]

  • 10. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
    Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M.
    Hepatogastroenterology; 2007 Mar 01; 54(74):508-13. PubMed ID: 17523309
    [Abstract] [Full Text] [Related]

  • 11. Progesterone increases epirubicin's apoptotic effects in HepG2 cells by S phase cell cycle arrest.
    Chang WT, Lin HL, Chang KL, Ker CG, Huang MC, Chen JS, Kuo KK, Chen YL, Lee KT.
    Hepatogastroenterology; 2010 Mar 01; 57(97):107-13. PubMed ID: 20422883
    [Abstract] [Full Text] [Related]

  • 12. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.
    Ann Surg Oncol; 2009 Mar 01; 16(3):623-9. PubMed ID: 19130133
    [Abstract] [Full Text] [Related]

  • 13. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N.
    J Hepatobiliary Pancreat Surg; 2006 Mar 01; 13(6):537-42. PubMed ID: 17139428
    [Abstract] [Full Text] [Related]

  • 14. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS, Ramalho LN, Della Porta L, Zucoloto S.
    J Gastroenterol Hepatol; 2006 Aug 01; 21(8):1276-80. PubMed ID: 16872309
    [Abstract] [Full Text] [Related]

  • 15. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
    Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB, Lee YJ, Chun HJ, Choi BG, Byun JY, Yoon SK.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):9-15. PubMed ID: 16614848
    [Abstract] [Full Text] [Related]

  • 16. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D, Kagata Y, Ogata S, Tsuda H, Hatsuse K, Mochizuki H, Matsubara O.
    Pathol Int; 2006 Apr 01; 56(4):222-6. PubMed ID: 16634969
    [Abstract] [Full Text] [Related]

  • 17. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O.
    Hepatology; 2013 Sep 01; 58(3):1065-73. PubMed ID: 23532667
    [Abstract] [Full Text] [Related]

  • 18. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):79-87. PubMed ID: 16642371
    [Abstract] [Full Text] [Related]

  • 19. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
    Tischoff I, Tannapfel A.
    Zentralbl Chir; 2007 Aug 01; 132(4):300-5. PubMed ID: 17724632
    [Abstract] [Full Text] [Related]

  • 20. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL, Fogt F, Burke M, Murakata LA.
    Oncol Rep; 2002 Aug 01; 9(4):689-92. PubMed ID: 12066193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.